Tumor-associated antigen from glioma cell (TAA (general abbreviation; no specific canonical abbreviation for glioma TAAs))

Tumor-associated antigens from glioma cells refer to a diverse group of proteins that are abnormally expressed at higher levels in malignant glial tumors compared to normal brain tissue. These include mutated or overexpressed self-proteins such as TP53 (tumor suppressor), IDH1 (enzyme), C3 (complement component), TCF12 (transcription factor), ARHGAP9/30, CLEC7A, MAN2B1 among others[1][2]. They play roles in tumor progression and immune evasion but can also be recognized by the immune system if presented appropriately. This makes them attractive targets for cancer immunotherapy approaches like mRNA vaccines designed to stimulate an anti-tumoral immune response specifically against cells expressing these antigens. However, because they may also be present at lower levels on some healthy tissues ("self-antigen"), therapeutic strategies must balance efficacy with safety concerns regarding potential autoimmunity[3]. If you need information about a specific named molecule within this group—such as "TP53"—please specify so structured data can be provided at the single-molecule level rather than this broad category.

Other names

Glioma tumor-associated antigenGlioma TAAGBM tumor-associated antigen (for glioblastoma)Tumor antigens in gliomas

For drugs targeting these molecules (primarily immunotherapies): - Induction of immune response against tumor cells expressing the targeted antigen[1][2] - Activation of cytotoxic T lymphocytes via presentation by APCs